; entire checklist in Supplementary Desk S4) to determine their mutational status in tumors of enrolled individuals as a possible biomarker of therapeutic reaction. DNA was extracted from accessible tumor samples (Infusion web-site response was described as any community adverse party in addition to agony or bleeding/bruising within the infusion in… Read More